Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Core Viewpoint - Vivos Therapeutics, Inc. has announced a registered direct offering of 709,220 shares of common stock at a price of $4.935 per share, along with a concurrent private placement of short-term warrants to purchase the same number of shares at an exercise price of $4.81 per share [1][2]. Group 1: Offering Details - The gross proceeds from the offering are expected to be approximately $3.5 million before deducting fees and expenses [2]. - If fully exercised, the short-term warrants could provide an additional gross proceeds of approximately $3.4 million [2]. - The closing of the offering is anticipated to occur on or about December 24, 2024, pending customary closing conditions [1]. Group 2: Company Background - Vivos Therapeutics specializes in developing and commercializing treatments for sleep-related breathing disorders, including obstructive sleep apnea (OSA) and snoring in both adults and children [1][10]. - The Vivos Method is a clinically effective, non-surgical, non-invasive, and cost-effective solution for treating OSA, having been proven effective in over 47,000 patients worldwide [10][11]. - The company also markets SleepImage diagnostic technology for home sleep testing and offers training and services to dentists through its Vivos Integrated Practice (VIP) program [12].